Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART

Authors :: Rusconi, S.
Vitiello, P.
Adorni, F.
Colella, E.
Focà, E.
Capetti, A.F.
Meraviglia, P.
Abeli, C.
Bonora, S.
D' Annunzio, M.
Di Biagio, A.
Di Pietro, A.
Butini, L.
Orofino, G.
Farina, S.
D' Ettorre, G.
Francisci, D.
Soria, A.
Buonomini, A.R.
Tommasi, C.
Trotta, M.P.
Capasso, M.
Merlini, E.
Marchetti, G.C.
Source :: Journal of the International AIDS Society. November, 2010, Vol. 13, p44, 2 p.
Publication Year :: 2010
Abstract: 7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK<br />Purpose 15‐30% of HAART‐treated HIV‐1‐positive patients (pts) lack CD4+ increase despite full HIV viremia suppression. The increased risk for INR to progress till AIDS led us to investigate maraviroc (MVC) [...]

Subjects :: Maraviroc -- Dosage and administration -- Testing
Highly active antiretroviral therapy -- Dosage and administration -- Patient outcomes
HIV infection -- Drug therapy -- Development and progression
Health

Full Text Access

Tools